Licensing status

Publication and contact information

Infectious disease

Bacterial infection; infectious disease


In vitro and mouse studies identified 5-nitroimidazole
(5-NI) derivatives that could help treat drug-resistant bacterial and protozoan infections. In growth and survival assays for Giardia lamblia, Trichomonas vaginalis, Helicobacter pylori and Clostridium difficile, 44 of the 378 tested 5-NI derivatives were more effective against all 4 organisms than the parent compound metronidazole. In these assays, the 5-NI derivatives showed antimicrobial activity against multiple clinical isolates, including those resistant to metronidazole. In mouse models of giardiasis,
7 of 16 tested 5-NI derivatives showed greater antimicrobial activity against the parasite than metronidazole. Next steps include selecting specific indications for testing individual compounds.

SciBX 6(43); doi:10.1038/scibx.2013.1225
Published online Nov. 7, 2013

Patent pending; available for licensing

Miyamoto, Y. et al. Proc. Natl. Acad. Sci. USA; published online Oct. 7, 2013;
Contact: Lars Eckmann, University of California, San Diego, La Jolla, Calif.